Search

Search Constraints

You searched for: Author/Creator Francis, Anne

Search Results

1. Clinical effectiveness of symptomatic therapy compared with standard step-up care for the treatment of low-impact psoriatic oligoarthritis: the two-arm parallel group randomised POISE feasibility study. (November 2021)

3. First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global): a combined analysis of three multicentre, randomised, phase 3 trials. Issue 9 (September 2017)

4. Clinical effectiveness of symptomatic therapy compared with standard step-up care for the treatment of low-impact psoriatic oligoarthritis: the two-arm parallel group randomised POISE feasibility study. (March 2022)

5. Effect of a 2-week interruption in methotrexate treatment versus continued treatment on COVID-19 booster vaccine immunity in adults with inflammatory conditions (VROOM study): a randomised, open label, superiority trial. Issue 9 (September 2022)

6. Hormone replacement therapy (conjugated oestrogens plus bazedoxifene) for post-menopausal women with symptomatic hand osteoarthritis: primary report from the HOPE-e randomised, placebo-controlled, feasibility study. (October 2022)

7. Quality of life in patients with liver metastases from colorectal cancer treated with first-line selective internal radiotherapy (SIRT): EQ-5D, EORTC QLQ-C30 and LMC21 results from the FOXFIRE study. Issue 11 (November 2017)

9. Effects of temporarily suspending low-dose methotrexate treatment for 2 weeks after SARS-CoV-2 vaccine booster on vaccine response in immunosuppressed adults with inflammatory conditions: protocol for a multicentre randomised controlled trial and nested mechanistic substudy (Vaccine Response On/Off Methotrexate (VROOM) study). Issue 5 (3rd May 2022)

10. Quality of life in patients with liver metastases from colorectal cancer treated with first-line selective internal radiotherapy (SIRT): EQ-5D, EORTC QLQ-C30 and LMC21 results from the FOXFIRE study. (March 2018)